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Abstract
 
Mutations in the apolipoprotein (apo) B, E (LDL)
receptor gene and in the apolipoprotein B-100 gene are the
cause of familial hypercholesterolemia (FH) and of familial
defective apo B-100 (FDB), respectively. Whether these ab-
normalities lead to altered production or uptake of very low
density lipoprotein (VLDL) or intermediate density lipopro-
tein (IDL) has not been established previously. Therefore
VLDL and IDL apo B-100 kinetics were measured in seven
subjects with FH, in six subjects with FDB, and in five normo-
cholesterolemic controls using primed-constant infusions of
[1-
 
13
 
C]leucine. Absolute production rates (APR) of VLDL
apoB were higher in FH than in controls (27.1 
 
6
 
 1.9 vs. 17.9
 
6
 
 2.1 mg/kg/day 
 
P
 
 
 
,
 
 0.03). VLDL APR in FDB were between
those of FH and controls (24.3 
 
6
 
 4.8 mg/kg/day), and dem-
onstrated a relatively large inter-individual variability. The in-
crease in VLDL APR in FH resulted in higher fasting serum
triglyceride concentrations than in controls (
 
P
 
 
 
,
 
 0.05),
whereas in FDB triglycerides were between those observed in
FH and in controls. A significant correlation was observed be-
tween VLDL apoB APR and serum triglycerides in FH and in
FDB; the correlation coefficient for all subjects was 
 
r
 
 
 
5
 
 0.84
(
 
P
 
 
 
,
 
 0.0001), indicating that the major determinant of serum
triglyceride concentrations was VLDL apoB APR. IDL apoB
APR was lower in FH and in FDB compared to controls (
 
P
 
 
 
,
 
0.03 
 
P
 
 
 
,
 
 0.02, respectively): and its fractional catabolic rate
(FCR) was slightly lower in FH and in FDB, resulting in simi-
lar plasma IDL apoB concentrations in all three groups of
subjects. IDL apoB APR in FH were negatively correlated with
LDL cholesterol concentrations (
 
r
 
 
 
5
 
 
 
2
 
0.89; 
 
P
 
 
 
,
 
 0.001); LDL
cholesterol concentrations correlated positively with the part
of VLDL that did not appear in IDL (
 
r
 
 
 
5
 
 0.82 
 
P
 
 
 
,
 
 0.02), by-
passing therefore the delipidation cascade.  In conclusion
the data demonstrate increased VLDL apoB production rates
in FH. VLDL and IDL kinetics differ when LDL concentra-
tions are elevated either due to a LDL receptor defect or due
to defective apolipoprotein B-100.—
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Apolipoprotein B-100 represents a major protein
component of very low density lipoproteins (VLDL) se-
creted by the liver (1, 2). The amount of apoB leaving
the liver in VLDL is dependent on the intracellular
availability of triglyceride and cholesterol (3). After en-
tering the circulation, VLDL are delipidated by lipo-
protein lipase, leading to intermediate density lipopro-
teins (IDL), the main precursor of the atherogenic low
density lipoproteins (LDL).
Previous studies on production rates of VLDL and
IDL apoB-100 in patients with familial hypercholester-
olemia (FH) yielded contradictory results. Increased,
unchanged, or decreased VLDL and increased or un-
changed IDL apoB secretion rates were reported using
different methods for their measurement and calcula-
tion (4–6). Kinetic studies have not yet been per-
formed comparing subjects with FH and with familial
defective apoB-100 (FDB). FDB is an autosomal domi-
nantly inherited disorder caused by a point mutation in
the apoB-100 gene (7). Its prevalence in Switzerland is
higher than in other countries (1:200) (8). This results
in diminished binding activity of the defective apoB to
the LDL (apoB, E) receptor, and finally in increased se-
rum LDL-cholesterol concentrations.
The aim of the present study was to assess the impact
of defective LDL receptors and of defective apoB-100
on VLDL and IDL kinetics in humans. This question
was of particular interest as a recent study from our lab-
oratory (9) demonstrated that serum triglyceride con-
 
Abbreviations: apo, apolipoprotein; VLDL, very low density lipo-
protein; IDL, intermediate density lipoprotein; FH, familial hyper-
cholesterolemia; APR, absolute production rate; FDB, familial defec-
tive apolipoprotein B; FCR, fractional catabolic rate; BMI, body mass
index; TTR, tracer-to-tracee ratio.
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centrations were higher in subjects with FH than in
controls, whereas they were not increased but more
variable in subjects with FDB.
SUBJECTS AND PROCEDURES
 
Subjects
 
Thirteen hypercholesterolemic subjects (7 FH, 6
FDB) and five normocholesterolemic controls of both
sexes were studied after giving their informed consent.
Age and body mass index (BMI) were not significantly
different between the groups. Incidentally, sex distribu-
tion differed among the groups with more females in
the FH and control groups, and more men in the FDB
group (
 
Table 1
 
). Patients were selected from a cohort
followed regularly in our lipid clinic using the follow-
ing criteria. In familial hypercholesterolemia, LDL re-
ceptor alleles were analyzed for eight restriction frag-
ment length polymorphisms of LDL receptor alleles
(10). Inheritance of the alleles in their pedigrees was
then followed, haplotypes for each subject were con-
structed, and cosegregation analysis was performed. In
two subjects without relatives, FH was diagnosed by
clinical criteria (11). FDB was diagnosed by the pres-
ence of a point mutation at nucleotide 10,708 by asym-
metric allele-specific PCR, as described previously (9).
Lipid-lowering drugs were discontinued for at least 8
weeks prior to the study. All subjects consumed an
American Heart Association Step 1 diet (12). Control
subjects were selected as having total cholesterol con-
centrations 
 
,
 
6.0 mmol/l and fasting triglycerides 
 
,
 
2.0
mmol/l measured at two separate occasions within 2
weeks. ApoE genotypes (13) were E
 
3
 
/E
 
3
 
 in six of the
seven subjects with FH, in four of six with FDB, and in
five of five control subjects. One FH subject had
apoE
 
3
 
/E
 
4
 
, one FDB apo E
 
2
 
/E
 
3
 
, and another FDR sub-
ject apoE
 
4
 
/E
 
4
 
. All subjects were healthy during the
study period, consumed no drugs, maintained their
body weight and their low level of physical activity; their
serum liver enzymes, creatinine, creatinephosphoki-
nase, and red and white blood cell counts were within
normal limits during the study. The experimental pro-
tocol was approved by the Ethics Committee of the Uni-
versity Hospital of Basel, and all subjects gave their writ-
ten informed consent to participate.
 
Study protocol
 
VLDL and IDL apoB kinetics were measured accord-
ing to Cohn et al. (14) by primed-constant infusions of
[1-
 
13
 
C]leucine (99% enriched; Mass Trace Inc., Somer-
ville, MA). Each study was started at 7:00 
 
am
 
 after an
overnight fast. The priming dose was 10 
 
m
 
mol/kg body
weight, and the constant intravenous infusion rate was
10 
 
m
 
mol/kg per h for 14 h, delivered by a portable infu-
sion pump (Secura Ft model, Braun, Melsungen, Ger-
many). In 3 of the 18 infusion studies, the tracer dosage
was increased to 20 
 
m
 
mol/kg (bolus) and to 20 
 
m
 
mol/kg
per h. During the kinetic study a primed continuous
postprandial state was maintained, in analogy to a previ-
ous study (14) by ingestion of a standardized liquid for-
mula diet containing 4% (w/v) proteins, 14% carbohy-
drates, and 3% lipids, consisting of 1.8% essential fatty
acids, and no cholesterol (Fresubin™, Fresenius, Swit-
zerland) in hourly portions of 1/14 of total daily energy
requirements during 14 h. Daily resting energy require-
ments were calculated using the Harris and Benedict
formula (15). Blood samples (20 ml) were drawn prior
to the hourly meals at 0, 1, 2, 3, 4, 5, 6, 7, 9, 11, 14 h.
 
Analytical methods
 
Serum cholesterol was determined enzymatically (kit
from Boehringer, Mannheim, Germany). HDL choles-
terol (HDL-C) was determined similarly after precipita-
tion of apoB-containing particles using reagents from
Boehringer, Mannheim, Germany. Serum triglycerides
were determined enzymatically (kit from Boehringer,
Mannheim, Germany). Plasma VLDL was isolated by se-
quential ultracentrifugation at a 1.006 g/ml, IDL at
d 1.019 g/ml using a Type Ti 70.1 rotor (Beekman,
Nyon, Switzerland) for both fractions. Sodium azide
was added to a final concentration of 0.1 mg/ml as an-
timicrobial agent, and EDTA to a final concentration of
0.5 m
 
m
 
. Samples were kept at 4
 
8
 
C during preparation
of the fractions, and stored at 
 
2
 
70
 
8
 
C. Total plasma
apoB, VLDL and LDL apoB concentrations were as-
sayed by nephelometry using a Behring apparatus and
a rabbit anti-human antibody (Behring AG, Marburg,
Germany). VLDL and IDL apo/B concentrations were
determined in duplicates of each sample. As there were
no significant changes of VLDL and IDL apoB concen-
trations during the infusion period, the mean of all
measurements was used for calculation of kinetics. The
coefficient of variation of VLDL apoB concentrations
was 17%, that of IDL apoB 13%. LDL apoB concentra-
tions were calculated as the difference between total
apoB and the sum of VLDL and IDL apoB.
 
TABLE 1. Patient characteristics
 
FH
 
(n 
 
5
 
 7)
 
FDB
 
(n 
 
5
 
 6)
 
Controls
 
(n 
 
5
 
 5)
Age (yrs) 50 
 
6
 
 5 47 
 
6
 
 7 32 
 
6
 
 6
BMI (kg/m
 
2
 
) 25 
 
6
 
 0.9 25 
 
6
 
 2 22 
 
6
 
 1
 
Sex (female/male) 
 
6/1
 
2/4
 
1/4
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For measurement of [
 
13
 
C]leucine content, apoB-100
was isolated from the VLDL and IDL fractions by pre-
parative SDS electrophoresis, and thyroglobuline from
Bio-Rad, Glattbrugg, Switzerland. VLDL and IDL apoB-
100 bands were excised from the polyacrylamide gels
and hydrolyzed at 110
 
8
 
C for 16 h in 6 
 
m
 
 HCl. The hy-
drolysates containing amino acids were added directly
to cation exchange columns (Bio-Rad, Glattbrugg, Swit-
zerland) to separate free leucine by eluting with 5 
 
m
 
NH
 
4
 
OH. The samples were dried in a Speed Vac evapo-
rator (Savant Instruments, Farmingdale, NY), and 100
 
m
 
l acetonitrile and 100 
 
m
 
l of MBDSTFA (Fluka, Buchs,
Switzerland) were added. Samples were analyzed using
a gas chromatograph mass spectrometer (5890/5870,
Hewlett-Packard, Palo Alto, CA). Selective ion monitor-
ing at 301 and 302 m/e was used to determine sample
tracer to tracee ratio (TTR) in leucine (16). Plasma 
 
a
 
-
ketoisocaproate (
 
a
 
-KIC) was derivatized by 
 
o
 
-phenyle-
nediamine (Sigma, St. Louis, MO) and MBDSTFA, and
selective ion monitoring at 259 and 260 m/e was used
to determine 
 
a
 
-KIC TTR. All stable isotope analyses
were run in duplicates.
 
Calculations
 
For estimation of fractional catabolic rates (FCR),
the Leverberg-Marquardt method (Quantum Soft, Zur-
ich, Switzerland) was used for non-linear curve fitting
and slope estimation of the change of leucine TTR with
time. Data were calculated by the function: A
 
apoB
 
 (t) 
 
5
 
A
 
a
 
-KIC
 
(1 – e
 
2
 
b
 
(t
 
2
 
0.5)
 
), where A
 
apoB
 
 (t) was the TTR of
[1-
 
13
 
C]leucine in apoB at time t, A
 
a
 
-KIC
 
 the TTR of
plasma [1-
 
13
 
C]-
 
a
 
-KIC, reflecting intracellular [
 
13
 
C]leu-
cine enrichment (17), 
 
b
 
 the rate constant, and 
 
2
 
0.5
(h) the intrahepatic delay time. The latter was deter-
mined from the time course of [l-
 
13
 
C]leucine TTR re-
ported previously (18), and from the data of the
present study (Fig. 1).
FCR was then calculated as:
The mean of three consecutive measurements of [1-
 
13
 
C]-
 
a
 
-KIC TTR obtained between 9 and 14 h at pla-
teau was used.
Absolute production rates (APR) of VLDL and IDL
apoB were calculated as:
where the apoB pool size was the apoB concentration
(mg/dl) in the respective lipoprotein fraction 
 
3
 
plasma volume (0.045 L/kg). The fraction of VLDL
FCR pools day⁄( ) =
rate of increase of leucine apoB TTR/h
1 C13–[ ] a– KIC TTR–
--------------------------------------------------------------------------------------------- 24 h·
APR mg kg day⁄⁄( ) =
FCR pools day⁄( ) apoB pool size mg( )·
body weight kg( )------------------------------------------------------------------------------------------------------
 
apoB that did not appear in IDL, and therefore by-
passed the delipidation cascade, was calculated as:
 
Statistical analyses
 
Results are means 
 
6
 
 SEM. Mann-Whitney-U-tests
were performed using Statview (Abacus Concepts Inc.)
on Macintosh computers. For correlation analyses the
Spearman rank correlation method was applied.
RESULTS
 
Baseline lipid and apo- and lipoprotein concentrations 
(Table 2)
 
Subjects with FH and FDB had higher total and LDL
cholesterol and apoB concentrations than controls
(
 
P
 
 
 
,
 
 0.005 and 
 
P
 
 
 
,
 
 0.02, respectively). VLDL apoB and
serum triglyceride concentrations were increased in FH
compared to controls (P , 0.05); HDL-C concentra-
tions were lower in FH and in FDB than in controls
(both P , 0.005).
Kinetic studies
Figure 1 shows the time course of [1-13C]leucine
TTR in VLDL and IDL apoB in FH subjects during the
14-h tracer infusion. VLDL and IDL TTR increased af-
ter a delay of approx. 0.5 to 1 h, reaching a near-
plateau for VLDL after approx. 10 h. [1-13C]leucine
TTR in IDL increased during the entire study and did
not reach an entirely steady state during the final sam-
pling period. VLDL apoB APR (Fig. 2, Table 2) were
higher in FH than in controls (P , 0.03). Mean VLDL
apoB APR in subjects with FDB were between those of
FH and controls. VLDL apoB FCR was not significantly
different among the three groups of subjects. The
VLDL apoB pool was increased in FH compared to con-
trols (P , 0.01); in FDB subjects, the mean VLDL apoB
13 pool was between FH and controls. IDL apoB APR
was lower in FH and in FDB than in controls (P , 0.03,
P , 0.02, respectively). FCR and apoB pool size of IDL
was similar in the three groups of subjects. The fraction
of VLDL apoB not appearing in IDL and therefore not
entering the delipidation cascade was 24 6 18% in con-
trols and higher in FH (72 6 5%; P , 0.04), and in
FBD (75 6 7%; P , 0.01). Individual VLDL and IDL ki-
netic data are shown in Table 3. The results demon-
strate a relatively large inter-individual variability of the
data. The fact that two control subjects demonstrated a
VLDL apoB bypass fraction (%) =
VLDL APR IDL APR–( ) 100·
VLDL APR-----------------------------------------------------------------------------
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negative VLDL fraction bypassing IDL suggests de novo
IDL production.
Correlation analyses
VLDL apoB APR and serum triglyceride concentra-
tions were significantly correlated in the subjects with
FH and with FDB (r 5 0.86, r 5 0.95, respectively). The
correlation of VLDL apoB APR and serum triglycerides
in all three groups of subjects together was r 5 0.84, P ,
0.0001 (Fig. 3). IDL kinetics were dependent on LDL
cholesterol plasma concentrations in FH subjects: IDL
production rates were decreased in subjects with
increased serum LDL-C concentrations (r 5 20.89, P
, 0.01), and the fraction of VLDL disappearing with-
out conversion into IDL was correlated with LDL-C
concentrations (r 5 0.82, P , 0.02; Fig. 4). The frac-
tion of VLDL disappearing without conversion to IDL
correlated negatively in FDB subjects (r 5 20.94, P ,
0.005; Fig. 4, bottom panel); this was of interest as
thereby normocholesterolemic FDB subjects demon-
strated a considerably higher fraction of VLDL disap-
pearing without conversion into IDL compared to sub-
jects of the control group with similar cholesterol
concentrations.
DISCUSSION
The results demonstrate that subjects with FH have
higher VLDL apoB production rates than normocho-
lesterolemic controls, whereas VLDL apoB APR in FDB
subjects are between those of FH and controls. In com-
parison, the fractional catabolic rates of VLDL were
similar in the three groups of subjects, indicating that
neither the defective LDL receptor function nor the
defective apoB-100 results in impaired VLDL removal.
TABLE 2. Serum lipoprotein and apolipoprotein B concentrations and VLDL and IDL apoB kinetics
FH
(n 5 7)
FDB
(n 5 6)
Controls
(n 5 5)
Serum lipid and lipoprotein concentrations
Triglycerides (mmol/l) 2.0 6 0.4a 1.6 6 0.4 1.0 6 0.3
Total cholesterol (mmol/l) 9.2 6 0.5c 7.7 6 0.6b 5.3 6 0.2
LDL-C (mmol/l) 7.3 6 0.5c 6.0 6 0.5c 2.8 6 0.2
HDL-C (mmol/l) 1.3 6 0.1c 1.2 6 0.2c 2.0 6 0.1
Apoprotein B concentrations
Total apoB (mg/dl) 245 6 20c 202 6 19b 107 6 11
VLDL apoB (mg/dl) 10.0 6 1.5a 7.8 6 1.8 5.8 6 0.5
IDL apoB (mg/dl) 5.0 6 0.7  4.5 6 1.2 5.4 6 0.5
LDL apoB (mg/dl) 230 6 16c 190 6 20c 96 6 6
VLDL and IDL kinetics
VLDL apoB pool (mg) 309 6 43b 249 6 45 162 6 21
VLDL apoB FCR (pools/day) 6.6 6 0.8 7.0 6 0.8 6.9 6 0.8
VLDL apoB APR (mg/kg/day) 27 6 2a 24 6 5 18 6 2.1
IDL apoB pool (mg) 156 6 21 133 6 25 146 6 8
IDL apoB FCR (pools/day) 3.4 6 0.5 2.7 6 0.4 5.6 6 1.5
IDL apoB APR (mg/kg/day) 7.4 6 1.1a 5.5 6 1.5b 1.25 6 1.9
Percentage of VLDL APR not appearing in IDL 72 6 5a 75 6 7b 24 6 18
Results are means 6 SEM.
aP , 0.05; bP , 0.02; cP , 0.005 versus controls.
Fig. 1. Time course of tracer to tracee ratio (TTR) of [1-13C]leu-
cine in VLDL (top) and IDL (bottom) apoB in 7 FH subjects, ex-
pressed as percent of plasma a-KIC–TTR (means 6 SEM).
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Compared to previously published data, the absolute
production rates of VLDL apoB in control subjects of
the present study were in a similar range (present
study: 17.9 mg/kg/day; previous reports: 17.6 (9.9–
36.7) mg/kg/day [mean, range] (5, 7, 14, 19–26). The
control subjects of the present study were on the aver-
age 18 yrs younger than the subjects with FH; Millar et
al. (27) reported that VLDL apoB APR increased
slightly with age, however not to an extent explaining
the present results in FH subjects. Increased VLDL
apoB APR in FH were also reported by Cummings et al.
(4), using similar tracer methods and data analysis, ex-
cept that their subjects were studied in the fasting state.
This may explain the lower absolute VLDL apoB APR
observed in their study as the present subjects received
a liquid formula diet in order to mimic a postprandial
state, resulting in increased VLDL apoB secretion (14).
The positive correlation between VLDL apoB APR
and fasting serum triglycerides observed in the present
study indicates that increased production of triglycer-
ide-containing lipoproteins explains the modest in-
crease in serum triglycerides in FH (11). Increased up-
take of cholesterol via receptor-independent pathways
may stimulate VLDL apoB production in FH as intrahe-
patic cholesterol availability has been reported to be
rate limiting for VLDL secretion (28–30). In contrast to
the present data, Fisher et al. (5) described slightly but
not significantly lower VLDL apoB APR in FH com-
pared to controls. These discrepancies were presum-
ably due to patient selection as the seven FH subjects
(5) happened to have fasting serum triglycerides simi-
lar to their control subjects. In addition, the tracer
method did not include a direct measurement of VLDL
apoB plasma concentrations.
The mean IDL apoB APR in control subjects of the
present study (12.5 6 1.9 mg/kg/day) was similar to
that reported previously (11.1 [6.2–14.8 mg/kg/day]
[median, range]) (6, 21, 22, 25, 26). IDL apoB APR in
the present study were lower in FH and in FDB subjects
than in controls. These data are in agreement with a
previous study (21) but at variance with other reports
demonstrating similar (6) or increased (5) IDL apoB
production rates in FH. Possible reasons for these dis-
Fig. 2. VLDL and IDL apoB absolute production rates (APR) in
FH (j, n 5 7), FDB (*SS, n 5 6), and control (u, n 5 5) subjects.
Data are means 6 SEM.
TABLE 3. Individual data of VLDL and IDL apoB kinetics
Subject Diagn. Sex
VLDL
ApoB
Conc.
VLDL
ApoB
Pool
VLDL
ApoB
FCR
VLDL
ApoB
APR
IDL
ApoB
Conc.
IDL
ApoB
Pool
IDL
ApoB
FCR
IDL
ApoB
APR
VLDL
bypassing
IDLa
mg/dl mg pools/d mg/kg/d mg/dl mg pools/d mg/kg/d %
A. D. FH f 16.9 510 4.1 31.1 7.8 236 1.9 6.6 78.8
A. K. FH f 8.5 279 6.5 24.7 3.6 120 2.4 3.9 84.4
F. J. FH f 12.1 339 5.8 31.5 5.1 143 2.9 6.7 78.9
T. M. FH f 7.9 234 5.8 20.4 4.4 130 5.8 11.4 44.3
V. Y. FH f 9.4 284 6.0 25.4 5.4 162 3.8 9.3 63.4
W. E. FH f 10.8 369 7.0 33.8 6.6 224 3.4 9.9 70.6
W. A. FH m 4.5 151 11.0 22.5 2.4 78 3.8 4.1 81.9
B. E. FDB f 5.7 157 8.9 22.9 7.2 197 3.4 10.8 52.5
B. F. FDB m 7.2 222 8.9 28.6 4.0 123 3.6 6.4 77.6
N. R. FDB m 3.7 115 5.5 9.1 2.1 67 1.4 1.4 85.2
W. G. FDB f 15.9 386 5.3 37.8 8.7 211 1.9 7.4 80.4
W. M. FDB m 5.6 239 4.8 12.2 3.0 125 3.8 5.1 57.9
W. Y. FDB m 8.9 375 8.9 35.4 1.8 77 2.2 1.8 94.8
C. N. Control f 7.3 190 7.9 25.9 6.2 162 3.6 10.0 61.3
D. N. Control f 4.6 112 8.9 18.4 5.5 134 3.1 7.7 58.0
H. B. Control f 6.0 149 5.3 14.3 5.3 131 6.0 14.3 20.4
K. C. Control f 5.0 135 7.4 16.7 6.3 170 4.1 11.6 30.9
R. C. Control m 6.3 227 5.0 14.3 3.7 133 11.3 18.8 231.4
aPercentage of VLDL not appearing in IDL, calculated as described in Methods.
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crepancies could be related to the tracer method or
data analysis used. Soutar, Myant, and Thompson (6)
used exogenous labeling of VLDL with 125I, a tech-
nique which may give rise to nonuniform labeling of
VLDL or to alteration of its metabolic behavior due to
the labeling process (31). Data reported by Fisher et al.
(5) were derived from calculated activity and not di-
rectly measured IDL specific activity. In contrast to the
lower IDL apoB APR in the present hypercholester-
olemic subjects, plasma concentrations of IDL apoB
were similar in all three groups of subjects. These data
may be explained by the fact that a limited capacity of
lipoprotein lipase to convert VLDL to IDL caused simi-
lar IDL apoB concentrations in hypercholesterolemic
subjects and in controls. These results are in contrast to
the increased IDL apoB concentrations reported in hy-
percholesterolemic Watanabe rabbits, animals with se-
verely impaired LDL receptor function (32).
VLDL and IDL apoB metabolism in subjects with FH
demonstrated several interesting features. First, IDL
apoB APR were negatively correlated with LDL choles-
terol concentrations. In addition, the fraction of VLDL
not appearing in IDL, and therefore bypassing the de-
lipidation cascade, was distinctly increased. In addition,
this fraction correlated positively with LDL concentra-
tions. Therefore, besides the increased VLDL pro-
duction in these subjects discussed above, a larger frac-
tion of VLDL compared to controls disappeared
without conversion into IDL, presumably via non-LDL-
receptor-dependent pathways. The higher the LDL
concentrations were in individual FH subjects, the
lower was the rate of VLDL not appearing in IDL, and
therefore the lower the rate of the IDL production.
These findings suggest that IDL are not the major di-
rect precursor of LDL in FH. A direct conversion of a
subfraction of VLDL to LDL was also suggested by
other authors using exogenous and endogenous label-
ing of lipoproteins (5).
Although it is not certain that all produced IDL was
isolated in this density 1.006–1.019 g/ml fraction, Beltz
et al. (33) also suggested that an IDL pool sequestered
in the liver in the space of Disse was transformed to
LDL without previous appearance in the circulation.
The metabolic pathways and mechanisms by which
VLDL subfractions are directly converted to LDL are
still poorly understood.
In comparison, FDB subjects demonstrated no clear
increase in VLDL apoB APR. This suggests that in FH,
the increase in VLDL apoB APR was due to a LDL-
receptor-mediated mechanism which may have re-
sulted from impaired catabolism of all apoB-containing
particles including VLDL remnants. Nevertheless, even
FDB subjects demonstrated an increased fraction of
Fig. 3. Relationship between VLDL apoB APR and fasting se-
rum triglyceride concentrations. Filled circles are subjects with
FH, open circles subjects with FDB, and filled triangles control
subjects, respectively. The correlation coefficient was r 5 0.84, P ,
0.001 (Spearman Rank test).
Fig. 4. Relationship between the percentage of VLDL apoB not
appearing in IDL, and serum LDL-C concentrations in FH (top
panel) and in FDB subjects (bottom panel). r values are Spear-
man Rank correlation coefficients.
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VLDL not appearing in IDL. The subjects with the
highest fraction of VLDL not appearing in IDL were
those with relatively low LDL-C concentrations, suggest-
ing that these individuals were protected from the de-
velopment of hypercholesterolemia due to diminished
VLDL-IDL-LDL conversion. It would be of interest to
know the kinetics of the two species of apoB in lipopro-
teins in subjects with FDB (wild type and defective
apoB); the present results are pooled data of both spe-
cies; whether the defective apoB is responsible for the
diminished VLDL-IDL-LDL cascade in FDB is likely but
not proven by the present results.
The sex distribution in the three groups of subjects
started was unbalanced, demonstrating a relatively
larger number of men than women in the FDB group.
The effect of gender on VLDL and IDL kinetics has not
been studied; however, when looking at individual data
(Table 3) there was no systematic difference between
both sexes in all groups.
In conclusion, the present results suggest that in-
creased VLDL apoB production rates in subjects with
FH are the cause of an increase in fasting serum triglyc-
eride concentrations. VLDL apoB catabolic rates and
fasting triglycerides in subjects with FDB were lower but
more variable compared to those in FH, suggesting
that apoB, E-receptor-mediated uptake of VLDL or IDL
may vary in individual FDB subjects according to other
factors, e.g., dietary habits. Thus, different alterations
of VLDL and IDL apoB kinetics occur when mutations
affect either the function or the ligand of the apoB, E
(LDL) receptor.
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